These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 32811475)

  • 41. Changes in metabolic parameters and cardiovascular risk factors after therapeutic control of acromegaly vary with the treatment modality. Data from the Bicêtre cohort, and review of the literature.
    Briet C; Ilie MD; Kuhn E; Maione L; Brailly-Tabard S; Salenave S; Cariou B; Chanson P
    Endocrine; 2019 Feb; 63(2):348-360. PubMed ID: 30397873
    [TBL] [Abstract][Full Text] [Related]  

  • 42. What is the efficacy of switching to weekly pegvisomant in acromegaly patients well controlled on combination therapy?
    Muhammad A; van der Lely AJ; O'Connor RD; Delhanty PJ; Dal J; Dallenga AH; Feelders RA; Janssen JA; Jorgensen JO; Neggers SJ
    Eur J Endocrinol; 2016 May; 174(5):663-7. PubMed ID: 26903550
    [TBL] [Abstract][Full Text] [Related]  

  • 43. A Canadian multi-centre, open-label long-term study of Pegvisomant treatment in refractory acromegaly.
    Ezzat S; Gaspo R; Serri O; Ur E; Chik CL
    Clin Invest Med; 2009 Dec; 32(6):E265. PubMed ID: 20003832
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3.
    Franck SE; van der Lely AJ; Delhanty PJ; Jørgensen JO; Neggers SJ
    Eur J Endocrinol; 2015 Nov; 173(5):553-61. PubMed ID: 26243033
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.
    Gadelha MR; Bronstein MD; Brue T; Coculescu M; Fleseriu M; Guitelman M; Pronin V; Raverot G; Shimon I; Lievre KK; Fleck J; Aout M; Pedroncelli AM; Colao A;
    Lancet Diabetes Endocrinol; 2014 Nov; 2(11):875-84. PubMed ID: 25260838
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy and safety of monotherapy by pegvisomant, a growth hormone receptor antagonist, in Japanese patients with acromegaly.
    Shimatsu A; Nagashima M; Hashigaki S; Ohki N; Chihara K
    Endocr J; 2016 Apr; 63(4):337-47. PubMed ID: 26796763
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Pharmacological management of acromegaly: a current perspective.
    Manjila S; Wu OC; Khan FR; Khan MM; Arafah BM; Selman WR
    Neurosurg Focus; 2010 Oct; 29(4):E14. PubMed ID: 20887124
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Elevated transaminases during medical treatment of acromegaly: a review of the German pegvisomant surveillance experience and a report of a patient with histologically proven chronic mild active hepatitis.
    Biering H; Saller B; Bauditz J; Pirlich M; Rudolph B; Johne A; Buchfelder M; Mann K; Droste M; Schreiber I; Lochs H; Strasburger CJ;
    Eur J Endocrinol; 2006 Feb; 154(2):213-20. PubMed ID: 16452533
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Growth hormone receptor antagonists.
    van der Lely AJ; Kopchick JJ
    Neuroendocrinology; 2006; 83(3-4):264-8. PubMed ID: 17047392
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Which patients with acromegaly are treated with pegvisomant? An overview of methodology and baseline data in ACROSTUDY.
    Brue T; Castinetti F; Lundgren F; Koltowska-Häggström M; Petrossians P;
    Eur J Endocrinol; 2009 Nov; 161 Suppl 1():S11-7. PubMed ID: 19684051
    [TBL] [Abstract][Full Text] [Related]  

  • 51. High-Dose and High-Frequency Lanreotide Autogel in Acromegaly: A Randomized, Multicenter Study.
    Giustina A; Mazziotti G; Cannavò S; Castello R; Arnaldi G; Bugari G; Cozzi R; Ferone D; Formenti AM; Gatti E; Grottoli S; Maffei P; Maffezzoni F; Montini M; Terzolo M; Ghigo E
    J Clin Endocrinol Metab; 2017 Jul; 102(7):2454-2464. PubMed ID: 28419317
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pegvisomant in combination or pegvisomant alone after failure of somatostatin analogs in acromegaly patients: an observational French ACROSTUDY cohort study.
    Kuhn E; Caron P; Delemer B; Raingeard I; Lefebvre H; Raverot G; Cortet-Rudelli C; Desailloud R; Geffroy C; Henocque R; Brault Y; Brue T; Chanson P
    Endocrine; 2021 Jan; 71(1):158-167. PubMed ID: 32986202
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis.
    Leonart LP; Ferreira VL; Tonin FS; Fernandez-Llimos F; Pontarolo R
    Value Health; 2018 Jul; 21(7):874-880. PubMed ID: 30005760
    [TBL] [Abstract][Full Text] [Related]  

  • 54. ACROSTUDY: Status Update on 469 Patients.
    Brue T
    Horm Res; 2009 Jan; 71 Suppl 1():34-8. PubMed ID: 19153503
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Pegvisomant treatment in patients with acromegaly in clinical practice: The French ACROSTUDY.
    Chanson P; Brue T; Delemer B; Caron P; Borson-Chazot F; Zouater H;
    Ann Endocrinol (Paris); 2015 Dec; 76(6):664-70. PubMed ID: 26596374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The place of pegvisomant in the acromegaly treatment algorithm.
    Paisley AN; Trainer PJ; Drake WM
    Growth Horm IGF Res; 2004 Jun; 14 Suppl A():S101-6. PubMed ID: 15135788
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Somatostatin analog and pegvisomant combination therapy for acromegaly.
    Neggers SJ; van der Lely AJ
    Nat Rev Endocrinol; 2009 Oct; 5(10):546-52. PubMed ID: 19763127
    [TBL] [Abstract][Full Text] [Related]  

  • 58. The effect of acute application of pegvisomant alone and in combination with octreotide on endogenous GH levels during a 6-h test in patients with acromegaly on constant pegvisomant treatment.
    Roemmler J; Steffin B; Gutt B; Sievers C; Bidlingmaier M; Schopohl J
    Growth Horm IGF Res; 2009 Jun; 19(3):245-51. PubMed ID: 19109045
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Alternate-day administration of pegvisomant maintains normal serum insulin-like growth factor-I levels in patients with acromegaly.
    Jehle S; Reyes CM; Sundeen RE; Freda PU
    J Clin Endocrinol Metab; 2005 Mar; 90(3):1588-93. PubMed ID: 15585549
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Brazilian multicenter study on pegvisomant treatment in acromegaly.
    Boguszewski CL; Huayllas MKP; Vilar L; Naves LA; Ribeiro-Oliveira Junior A; Soares BS; Czepielewski MA; Abucham J; Correa-Silva SR; Bronstein MD; Jallad RS; Duarte FG; Musolino NR; Kasuki L; Gadelha MR
    Arch Endocrinol Metab; 2019 Jul; 63(4):328-336. PubMed ID: 31365632
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.